Highlight Therapeutics, S.L.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Highlight Therapeutics, S.L.
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
After investing more than €23m in Sanifit, the Spanish firm being acquired by Vifor Pharma, Caixa Capital's director of life sciences investments spoke to Scrip about the venture capital firm's long-term approach.
Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.
After a decade of research, the Spanish biotech believes its lead candidate BO-112 can turn ‘cold’ tumors ‘hot,' offering the potential to rescue patients who are resistant to current checkpoint inhibitor therapy.
- Other Names / Subsidiaries
- Bioncotech Therapeutics S.L